Roche’s Skin-Cancer Drug Erivedge Wins EU Agency Backing
This article is for subscribers only.
Roche Holding AG won the backing of a European advisory panel for its skin-cancer medicine Erivedge, a step forward in the Swiss drugmaker’s plan to market the non-surgical, non-radiation treatment for people with advanced forms of the most common type of skin cancer.
Roche should be given conditional approval to sell the drug as a treatment for basal cell carcinoma that has spread or can’t be treated with surgery or radiotherapy, the London-based European Medicines Agency’s Committee for Medicinal Products for Human Use said in a statement on its website today. The European Commission usually follows the panel’s advice.